Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of Convalescent Plasma in Mechanically Ventilated COVID-19 Patients
NCT04353206Phase 1Terminated
- Start
- Jun 2020
- Primary completion
- Nov 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19) and respiratory failure. Primary endpoint: Proportion of subjects who consent and receive at least one dose of convalescent plasma at 60 days. Started Jun 2020; status: terminated.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)respiratory failure
Beyond the preview
Go deeper on NCT04353206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04353206.